Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Oncomed Pharmaceuticals Company Profile (NASDAQ:OMED)

Consensus Ratings for Oncomed Pharmaceuticals (NASDAQ:OMED) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $30.45 (50.44% upside)

Analysts' Ratings History for Oncomed Pharmaceuticals (NASDAQ:OMED)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/19/2014BMO Capital MarketsReiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
10/13/2014ZacksUpgradeUnderperform -> Neutral$17.80ViewTweet This Rating  Share This Rating on StockTwits
10/7/2014JMP SecuritiesInitiated CoverageOutperform$28.00ViewTweet This Rating  Share This Rating on StockTwits
10/7/2014Jefferies GroupInitiated CoverageMarket Outperform$28.00ViewTweet This Rating  Share This Rating on StockTwits
8/28/2014BMO Capital MarketsReiterated RatingHoldViewTweet This Rating  Share This Rating on StockTwits
8/12/2014ZacksDowngradeNeutral -> Underperform$15.00ViewTweet This Rating  Share This Rating on StockTwits
6/13/2014MizuhoReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
5/9/2014Jefferies GroupLower Price Target$50.00 -> $48.00ViewTweet This Rating  Share This Rating on StockTwits
2/10/2014MizuhoInitiated CoverageBuy$45.00ViewTweet This Rating  Share This Rating on StockTwits
1/17/2014Piper JaffrayBoost Price Target$48.00ViewTweet This Rating  Share This Rating on StockTwits
12/4/2013Jefferies GroupBoost Price TargetBuy$27.00 -> $46.00ViewTweet This Rating  Share This Rating on StockTwits
8/12/2013BMO Capital MarketsInitiated CoverageOutperform$32.00ViewTweet This Rating  Share This Rating on StockTwits
8/12/2013Leerink SwannInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
8/12/2013Piper JaffrayInitiated CoverageOverweight$30.00 -> $19.84ViewTweet This Rating  Share This Rating on StockTwits
8/12/2013Jefferies GroupInitiated CoverageBuy$27.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 12/18/2012 forward)